Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.52 |
| ▸ | NPC1 | O15118 | 4/20 | 0.52 |
| ▸ | RAB9A | P51151 | 4/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.52 |
| ▸ | ALPL | P05186 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | GRK6 | P43250 | 2/20 | 0.52 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | F10 | P00742 | 1/20 | 0.44 |
| ▸ | PLG | P00747 | 1/20 | 0.44 |
| ▸ | PLAU | P00749 | 1/20 | 0.44 |
| ▸ | PLAT | P00750 | 1/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6452551 | 0.88 | GRK6 (0.56) | SMN1; SMN2L3MBTL1NPC1RAB9ATDP1 | |
| SCHEMBL6452705 | 0.85 | GRK6 (0.51) | SMN1; SMN2L3MBTL1NPC1RAB9ATDP1 | |
| SCHEMBL6452115 | 0.82 | GRK6 (0.50) | SMN1; SMN2L3MBTL1NPC1RAB9ATDP1 | |
| SCHEMBL6450488 | 0.81 | GRK6 (0.49) | SMN1; SMN2L3MBTL1NPC1RAB9ATDP1 | |
| SCHEMBL6451280 | 0.81 | GRK6 (0.48) | L3MBTL1NPC1RAB9AHSD17B10GRK6 | |
| SCHEMBL6448759 | 0.80 | GRK6 (0.48) | L3MBTL1NPC1RAB9AGRK6F2 | |
| SCHEMBL6451923 | 0.79 | SMN1; SMN2 (0.69) | SMN1; SMN2L3MBTL1NPC1RAB9ATDP1 | |
| SCHEMBL6450451 | 0.78 | NPC1 (0.56) | SMN1; SMN2L3MBTL1NPC1RAB9ATDP1 | |
| SCHEMBL6461029 | 0.75 | SMN1; SMN2 (0.52) | SMN1; SMN2L3MBTL1NPC1RAB9ATDP1 | |
| SCHEMBL6453993 | 0.75 | NPC1 (0.58) | SMN1; SMN2L3MBTL1NPC1RAB9ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| WO-2004110351-A2 | HETEROCYCLIC COMPOUNDS FOR TREATING HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | HAVCR2, HCCS, LIPC | SMN1; SMN2 4633/4885L3MBTL1 4366/4885NPC1 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.